Insys Therapeutics closed at $4.62 in the latest trading session, marking a +1.99% move from the prior day. This move outpaced the S&P 500's daily gain of 0.67%. At the same time, the Dow added 0.82%, and the tech-heavy Nasdaq gained 0.78%.
Prior to today's trading, shares of the specialty pharmaceutical company had lost 27.98% over the past month. This has lagged the Medical sector's gain of 0.38% and the S&P 500's gain of 1.25% in that time.
INSY will be looking to display strength as it nears its next earnings release. On that day, INSY is projected to report earnings of -$0.13 per share, which would represent year-over-year growth of 31.58%. Meanwhile, our latest consensus estimate is calling for revenue of $14.95 million, down 37.47% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.86 per share and revenue of $60.84 million, which would represent changes of +32.28% and -25.88%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for INSY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 44.86% lower. INSY is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know
Insys Therapeutics closed at $4.62 in the latest trading session, marking a +1.99% move from the prior day. This move outpaced the S&P 500's daily gain of 0.67%. At the same time, the Dow added 0.82%, and the tech-heavy Nasdaq gained 0.78%.
Prior to today's trading, shares of the specialty pharmaceutical company had lost 27.98% over the past month. This has lagged the Medical sector's gain of 0.38% and the S&P 500's gain of 1.25% in that time.
INSY will be looking to display strength as it nears its next earnings release. On that day, INSY is projected to report earnings of -$0.13 per share, which would represent year-over-year growth of 31.58%. Meanwhile, our latest consensus estimate is calling for revenue of $14.95 million, down 37.47% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.86 per share and revenue of $60.84 million, which would represent changes of +32.28% and -25.88%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for INSY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 44.86% lower. INSY is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.